CDMO Kindeva has announced that David Stevens has taken over the role of CEO, effective January 1, 2026. Stevens succeeds Milton Boyer, who will remain a member of the board of directors, the company said. Stevens joined Kindeva in 2023 as Chief Commercial Officer and Kindeva announced his promotion to President in October 2025.
Kindeva (formerly 3M Drug Delivery Systems) was sold by 3M to Altaris is 2019, and has recently been increasing its capabilities for development and manufacturing of inhaled and nasal drugs. Kindeva has added analytical facilities in the US and in the UK, and the company’s manufacturing facilitiy in Loughborough, UK recently took delivery of an ISO tank of HFA-152a as part of its focus on the LGWP propellant transition where an additional LGWP propellant MDI manufacturing line was added in 2024. Also in 2024, Kindeva acquired nasal delivery specialist Summit Biosciences.
Stevens commented, “I am deeply honored to have the opportunity to succeed Milton as Kindeva’s Chief Executive Officer and look forward to building on his success. Kindeva’s unique heritage of innovation, industry leading capabilities, and our dedicated expert employees, means we have an exciting future ahead. Our focus remains on driving growth and performance by offering best-in-class drug delivery solutions while continuing to provide exceptional service and reliability for our customers. I feel incredibly privileged to lead Kindeva into this next chapter and work alongside our talented team to achieve our ambitious goals.”
Altaris Managing Director George Aitken-Davies said, “Kindeva has made significant progress in building a strong foundation for growth. Under David’s leadership, we are well-positioned to execute our strategy and deliver value for customers, employees, and stakeholders. We thank Milton for his innumerable contributions as CEO, and look forward to his ongoing involvement at the Board level.”
Read the Kindeva press release
